Molecular Profiling Is Rather Likely to Be Cost Effective

Valesca P. Retel; Sabine C. Linn; Wim H. van Harten

doi:10.1200/JCO.2014.59.8029

Molecular Profiling Is Rather Likely to Be Cost Effective

Valesca P. Retel^*
, Sabine C. Linn
, Wim H. van Harten

^*Corresponding author for this work

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

Original language	English
Pages (from-to)	1626-627
Number of pages	2
Journal	Journal of Clinical Oncology
Volume	33
Issue number	14
DOIs	https://doi.org/10.1200/JCO.2014.59.8029
Publication status	Published - 10 May 2015

Keywords

POSITIVE BREAST-CANCER
PHASE-III
GUIDELINES
SIGNATURE
TRIAL

Access to Document

10.1200/JCO.2014.59.8029

Cite this

@article{cf3dce0e93f743de9fbdbc2d5348395a,

title = "Molecular Profiling Is Rather Likely to Be Cost Effective",

keywords = "POSITIVE BREAST-CANCER, PHASE-III, GUIDELINES, SIGNATURE, TRIAL",

author = "Retel, \{Valesca P.\} and Linn, \{Sabine C.\} and \{van Harten\}, \{Wim H.\}",

year = "2015",

month = may,

day = "10",

doi = "10.1200/JCO.2014.59.8029",

language = "English",

volume = "33",

pages = "1626--627",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "Lippincott Williams \& Wilkins",

number = "14",

}

TY - JOUR

T1 - Molecular Profiling Is Rather Likely to Be Cost Effective

AU - Retel, Valesca P.

AU - Linn, Sabine C.

AU - van Harten, Wim H.

PY - 2015/5/10

Y1 - 2015/5/10

KW - POSITIVE BREAST-CANCER

KW - PHASE-III

KW - GUIDELINES

KW - SIGNATURE

KW - TRIAL

U2 - 10.1200/JCO.2014.59.8029

DO - 10.1200/JCO.2014.59.8029

M3 - Comment/Letter to the editor

SN - 0732-183X

VL - 33

SP - 1626

EP - 1627

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 14

ER -